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-Please see Detail-Document #200915 for our updated opioid comparison chart-

What It Is
Palladone is a new oral extended-release
hydromorphone product.
It is intended for
around-the-clock (ATC) administration in opioidexperienced patients requiring high potency
analgesia for an extended period of time. It is the
first long-acting hydromorphone product available
in the U.S. Hydromorphone is a potent opioid mu
receptor agonist producing analgesia as its
primary therapeutic action. Other actions include
anxiolysis, euphoria, and feelings of relaxation.1

Indications
Palladone capsules are indicated for the
management of persistent moderate to severe pain
in patients requiring continuous ATC highpotency opioid pain relief for an extended period
of time ranging from weeks to months or longer.1,2
It may be used in patients requiring a
minimum total daily dose of oral opioid therapy
equivalent to 12 mg of oral hydromorphone.
These patients must have already received opioid
therapy and demonstrated opioid tolerance.
Opioid-tolerant patients are those who are taking
at least one of the following:
• 60 mg of oral morphine per day,
• 30 mg of oral oxycodone per day,
• 8 mg of oral hydromorphone per day,
• or any other equianalgesic dose of another
opioid
for at least one week. It is not intended as
initiation opioid therapy, short term use, or “as
needed” therapy.1

How Supplied - Cost
The extended-release Palladone capsules are
available in 12 mg, 16 mg, 24 mg, and 32 mg
strengths in bottles of 60 capsules.1,3
The average wholesale product cost (AWP)
per capsule is: $7.70/12 mg, $8.99/16 mg,
$12.95/24 mg, and $16.71/32 mg.3

Product Formulation Considerations
Palladone capsules contain hydromorphone
HCl in a pellet formulation which uses a
controlled-release melt extrusion technology.
Each pellet contains the same amount of
hydromorphone with different capsule fill weights
used to vary strengths.
It is important to note that demonstrated
dosage form proportionality on a dose-adjusted
basis is three 12 mg capsules to one 32 mg
capsule.1
The terminal elimination half-life for
controlled
release
hydromorphone
is
approximately 18.6 hours.1
Palladone is formulated for once daily dosing.
The capsules must not be crushed or altered in any
way to assure maintenance of pellet integrity.
Otherwise,
rapid-release
can
result
in
hydromorphone overdose.1

Adverse Effects
The most frequent adverse events reported in
placebo-controlled clinical trials with an incidence
of at least 2% were constipation, nausea,
headache, somnolence, asthenia, vomiting, and
pruritus.1

Drug Interactions
As with other opioid agonists, concomitant
administration of CNS depressants with Palladone
may cause respiratory depression, hypotension,
profound sedation, and may result in coma.
Hydromorphone combined with skeletal muscle
relaxants can enhance neuromuscular blockade
and result in increased respiratory depression.
Mixed agonist-antagonist opioid analgesics such
as pentazocine, nalbuphine, and butorphanol
should be administered with caution due to the
potential for decreased hydromorphone analgesia
and precipitation of withdrawal responses.
More. . .
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MAOIs should be discontinued at least 14 days
prior to initiation of Palladone therapy.
Palladone’s bioavailability is not significantly
affected by food.1

Contraindications
Palladone is contraindicated for “as needed”
therapy, respiratory depression, acute or severe
bronchial asthma, diagnoses of or suspected
paralytic ileus, and those hypersensitive to
hydromorphone or any components in Palladone.1

Precautions and Warnings
Capsules must not be broken, chewed, opened,
dissolved, or crushed because of the grave
potential for fatal overdose. Palladone must only
be used in opioid-tolerant patients. As with all
CII opioid analgesics, there is increased risk and
concern about misuse, abuse, addiction, and
diversion. In the presence of head injury or
intracranial lesions, Palladone’s respiratory
depressant effects may be exaggerated and also
mask neurological signs of increasing intracranial
pressure. Orthostatic hypotension may occur in
ambulatory patients. Cautious use of Palladone
must occur in the presence of pancreatic or biliary
tract disease. Palladone must not be used in
patients with severe hepatic impairment and
careful dosage selection is recommended for those
with mild to moderate impairment.
Lower
dosages should be prescribed in patients with mild
to moderate renal impairment. Palladone should
be used with caution in patients with prior drug or
alcohol abuse, adrenocortical insufficiency,
debilitation, myxedema, hypothyroidism, prostatic
hypertrophy, urethral stricture, and toxic
psychosis.1

Use in Pregnancy
Palladone is a Pregnancy Category C drug.
There are no adequate and well-controlled studies
in pregnant women. It should be used only if the
need clearly outweighs the potential risks to the
fetus.1

Dosage
The dosage of Palladone is dependent on the
patient’s past opioid experience, tolerance, and
clinical considerations such as medical condition,
co-morbidity factors, concomitant therapy, abuse
history, and past pain control levels.1

Please see Detail-Document #200915,
Equianalgesic Dosing of Opioids for Pain
Management,4 which has been updated to reflect
Palladone dosing guidance.
Palladone extended-release capsules should be
swallowed whole and are administered only once
daily. All other ATC opioid products should be
discontinued when initiating Palladone therapy.
Patients may need immediate-release medication
for break-through pain control or for pain
prevention during certain periods of patient
activity. Palladone can be administered with nonopioid analgesics or other adjuvant therapy as
long as these are considered when selecting initial
Palladone dosage.1
When converting from other opioid analgesics
to Palladone, monitoring for possible overdose or
intolerance should occur. Monitoring for risks
such as respiratory depression, altered mental
status, and hypotension are essential. Because of
Palladone’s prolonged elimination half-life (18
hours) overestimation of initial dose requires
extended monitoring and treatment.1

Manufacturer
Purdue Pharma L.P.
Stamford, CT 06901-3431
800-877-5666
www.purduepharma.com

Commentary
Palladone is the first extended-release
hydromorphone product. Because of its release
characteristics it provides dosing at 24 hour
intervals and must be administered only once
daily. It offers an additional choice for opioidtolerant patients requiring ATC opioid analgesia.
Another product, Avinza, is an extendedrelease morphine formulation which is also
administered only once daily at 24 hour intervals.
Unlike Palladone, Avinza may be prescribed for
opioid-naïve patients starting at the lowest dose of
30 mg once-daily.5 Equianalgesic daily doses of
Palladone will cost slightly more (approximately
one-third more) than Avinza.3
Because Palladone is a potent Schedule II
opioid agonist, it presents a high risk for fatal
overdose and also potential abuse and diversion.
Purdue Pharma with the approval of the FDA has
a patient Medication Guide which must be
dispensed with each Palladone prescription. It is
More. . .
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available at: http://www.fda.gov/cder/foi/label
/2004/021044medicationguide.pdf.
The following excerpts are reprinted from the
September 24, 2004 FDA Talk Paper concerning FDA
approval of Palladone and the development of an
effective plan to reduce inappropriate use:
http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01
315.html.

The active ingredient in Palladone,
hydromorphone, is currently a Schedule II
controlled substance, which is the highest level of
control for drugs with a recognized medical use.
Based on the risks associated with the drug,
including the potential for abuse of Palladone,
FDA has worked with the sponsor to develop a
comprehensive risk management program (RMP).
The RMP was designed with three potential
risk situations identified. These are the risks
posed by improper dosing, indication, or patient
selection; the risk posed by accidental pediatric
exposure to the drug; and the risk posed by abuse
or diversion of Palladone capsules.
As a controlled substance in Schedule II of the
Controlled Substances Act (CSA), Palladone also
comes under the jurisdiction of the Drug
Enforcement Administration (DEA), which
administers the CSA. Schedule II drugs are
subject to manufacturing quotas set by DEA with
input on medical need from FDA, distribution
tracking, import and export controls, registration
of prescribers and dispensers, and written
prescriptions without refills.
In addition to the protection afforded patients
through the status of Palladone as a controlled
substance, the RMP includes provisions for clear
and appropriate labeling, and appropriate
education of healthcare professionals, patients,
and caregivers. In addition, the sponsor has
committed to offer appropriate training to sales
representatives.
To guard against the
inappropriate use of the drug, the RMP also
establishes a multifaceted program for monitoring
and surveillance of abuse. If abuse, misuse, and
diversion occur, the program includes an array of
interventions.
As part of the RMP, a Medication Guide
(FDA-approved patient information which is
required to be dispensed with each prescription)
has been written for patients prescribed

Palladone. FDA requires a Medication Guide
only when one or more of the following
circumstances exists: (1) the drug is one for which
patient labeling could help prevent serious adverse
effects; (2) the drug is one that has serious risks of
which patients should be made aware because
information concerning the risks could affect
patients' decision to use, or continue to use the
drug; and (3) the drug is important to health and
patient adherence to directions for use is crucial to
the drug's effectiveness. In addition, the physician
labeling for Palladone contains a “black box”
warning.
FDA is also part of a larger initiative to reduce
diversion and abuse of prescription drugs. On
March 1, 2004, the Office of National Drug
Control Policy was joined by the Surgeon
General, the DEA Administrator, and the FDA
Commissioner to announce the National Drug
Control Strategy. The strategy emphasized new
collaborative efforts at the federal, state, and local
levels to prevent and reduce diversion and abuse
of prescription drugs. This strategy focused on
three core tactics: (1) Business Outreach and
Consumer Protection, (2) Investigation and
Enforcement, and (3) Protecting Safe and
Effective Use of Medications.
During the
approval
process
for
Palladone,
FDA
incorporated many of the elements of this strategy
as exhibited by inclusion of the “black box”
warnings on the labeling, the Medication Guide,
and the implementation of a RMP.

Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.

References
1.
2.

3.

Product information for Palladone. Purdue Pharma
L.P. Stamford, CT 06901-3431. September 2004.
Anon. FDA approves new extended release pain
medication: agency works with sponsor to develop
an effective plan to reduce inappropriate use. FDA
Talk Paper. September 24, 2004 (T04-40).
Cardinal Health Inc., www.cardinal.com (Accessed
February
9,
2005).

More. . .
Copyright © 2005 by Therapeutic Research Center
Pharmacist’s Letter / Prescriber’s Letter ~ P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.pharmacistsletter.com ~ www.prescribersletter.com

(Detail-Document #210308: Page 4 of 4)
4.

Obenrader, J. Equianalgesic dosing of opioids for
pain
management.
Pharmacist’s
Letter/Prescriber’s Letter. 2004;20(9):200915.

5.

Product information for Avinza.
Ligand
Pharmaceuticals Incorporated. San Diego, CA
92121. February 2003.

Cite this Detail-Document as follows: Palladone (hydromorphone extended-release capsules). Pharmacist’s
Letter/Prescriber’s Letter 2005;21(3):210308.
®

®

The most practical knowledge in the least time…
3120 West March Lane, P.O. Box 8190, Stockton, CA 95208 ~ TEL (209) 472-2240 ~ FAX (209) 472-2249
Copyright © 2005 by Therapeutic Research Center

Subscribers to Pharmacist’s Letter and Prescriber’s Letter can get Detail-Documents, like this one, on any
topic covered in any issue by going to www.pharmacistsletter.com or www.prescribersletter.com

